Clinical Trials Directory
We are doing this study to learn if SAPIEN 3 valve system is safe and will work with adults and children who have a dysfunctional right ventricular outflow tract (RVOT) conduit or have an implanted valve in the pulmonic position.
Patients will first get Td preconditioning and a medicine called temozolomide for 5 days. On day 21, they will get the study vaccine, PEP-CMV. The first 3 vaccines will be given every 2 weeks. After that, the vaccines will be given once a month. The first treatment cycle lasts 77 days, and all cycles after that last 28 days. To join the study, patients must have lab and clinical tests done within 7 days before starting. Lab results must be no more than 7 days old when therapy begins. If therapy starts within 7 days of the lab tests, the tests do not need to be repeated.
People in this study will visit the research center two times each month to see the study doctor. The study can last up to 2 years. Treatment happens in cycles, and each cycle is 28 days long, which is about 4 weeks. A person can have up to 26 cycles, which equals about 2 years of treatment. The amount of medicine given will depend on the person’s weight, which is checked before each new cycle. The medicine is called tocilizumab. It blocks a protein called interleukin-6, which causes swelling in the body. This medicine is usually used for diseases where the immune system attacks the body, like arthritis, and it can also help with a problem called cytokine release syndrome after certain cancer treatments.
We are doing this study to learn how to best support young women making decisions about breast cancer surgery. We want to know what makes women feel uncertain about their decision-making so we can become better at providing the information they need. This study involves testing a web-based decision support tool that is designed to help young women with newly diagnosed breast cancer with their surgical decisions.
People in the study will get a special medicine called CTIM-76 through a tube in their arm once a week. Each round of treatment lasts 4 weeks. They can keep getting the medicine as long as it helps and doesn’t cause too many problems. Doctors will check on them often with visits, blood tests, and scans to see if the medicine is working and if it’s safe. Some people will start with small doses, and the amount may go up as doctors learn more.
We are doing this study to find out if the use of continuous glucose monitors (CGMs) is worthwhile to help breast cancer patients and their providers monitor for hyperglycemia, or high blood sugar, during chemotherapy. A CGM is a small, wearable sensor that is attached to the skin to frequently measure your blood sugar level, and can share the measurements to your smartphone and to your medical team.
People in this study will do a one-time video interview that lasts between 30 minutes and 1 hour. The interview will ask questions about how they choose birth control and how having cancer has changed their thoughts and feelings about it. During the interview, they will also answer 16 questions on a survey to help researchers understand how confident they feel about making birth control decisions.